| Abstrakt: |
Recently, RIPK2 was also shown to stabilize and activate c-Myc, a molecule implicated in the progression of various malignancies including prostate cancer (PCa)." Keywords: Biomarkers; Cancer; Diagnostics and Screening; Drugs and Therapies; Health and Medicine; Oncology; Personalized Medicine; Personalized Therapy; Prognostic Markers; Prostate Cancer; Prostatic Neoplasms EN Biomarkers Cancer Diagnostics and Screening Drugs and Therapies Health and Medicine Oncology Personalized Medicine Personalized Therapy Prognostic Markers Prostate Cancer Prostatic Neoplasms 689 689 1 04/03/23 20230404 NES 230404 2023 APR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in personalized medicine. According to the news editors, the research concluded: "PCa is the most prevalent cancer in US males and there is an urgent need for more accurate biomarkers that can predict disease severity and suggest actionable targeted therapy. [Extracted from the article] |
